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Abstract
BACKGROUND—It is unclear whether using fetal electrocardiographic (ECG) ST-segment 
analysis as an adjunct to conventional intrapartum electronic fetal heart-rate monitoring modifies 
intrapartum and neonatal outcomes.
METHODS—We performed a multicenter trial in which women with a singleton fetus who were 
attempting vaginal delivery at more than 36 weeks of gestation and who had cervical dilation of 2 
to 7 cm were randomly assigned to “open” or “masked” monitoring with fetal ST-segment 
analysis. The masked system functioned as a normal fetal heart-rate monitor. The open system 
displayed additional information for use when uncertain fetal heart-rate patterns were detected. 
The primary outcome was a composite of intrapartum fetal death, neonatal death, an Apgar score 
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of 3 or less at 5 minutes, neonatal seizure, an umbilical-artery blood pH of 7.05 or less with a base 
deficit of 12 mmol per liter or more, intubation for ventilation at delivery, or neonatal 
encephalopathy.
RESULTS—A total of 11,108 patients underwent randomization; 5532 were assigned to the open 
group, and 5576 to the masked group. The primary outcome occurred in 52 fetuses or neonates of 
women in the open group (0.9%) and 40 fetuses or neonates of women in the masked group 
(0.7%) (relative risk, 1.31; 95% confidence interval, 0.87 to 1.98; P = 0.20). Among the individual 
components of the primary outcome, only the frequency of a 5-minute Apgar score of 3 or less 
differed significantly between neonates of women in the open group and those in the masked 
group (0.3% vs. 0.1%, P = 0.02). There were no significant between-group differences in the rate 
of cesarean delivery (16.9% and 16.2%, respectively; P = 0.30) or any operative delivery (22.8% 
and 22.0%, respectively; P = 0.31). Adverse events were rare and occurred with similar frequency 
in the two groups.
CONCLUSIONS—Fetal ECG ST-segment analysis used as an adjunct to conventional 
intrapartum electronic fetal heart-rate monitoring did not improve perinatal outcomes or decrease 
operative-delivery rates. (Funded by the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development and Neoventa Medical; ClinicalTrials.gov number, 
NCT01131260.)
CONTINUOUS INTRAPARTUM FETAL heart-rate monitoring has caused considerable controversy in 
obstetrics. Despite decades of use and an associated rise in cesarean-delivery rates based at 
least in part on nonreassuring fetal heart-rate patterns, evidence that such monitoring has 
reduced the rate of hypoxia-induced neonatal encephalopathy is lacking. In 2005, the Food 
and Drug Administration (FDA) granted conditional approval of the STAN S31 device 
(Neoventa Medical) for use as an adjunct to conventional electronic fetal heart-rate 
monitoring.1 This technology was designed to provide fetal electrocardiographic (ECG) 
information reflective of myocardial metabolism and acid–base balance. The rationale is that 
fetal acidemia is associated with fetal ECG ST-segment elevation and increased T-wave 
amplitude.2-6 The monitor for fetal ECG ST-segment analysis uses proprietary software to 
detect these ECG changes and then issues a visual alert (“ST event”) when these changes 
occur.
Initial FDA approval was based primarily on European studies7-9 that suggested that fetal 
ST-segment analysis technology reduced the rates of neonatal encephalopathy, acidemia, 
and operative delivery. However, the relevance of these results to usual obstetrical practice 
is unclear, given inconsistent findings among published trials and questions about eligibility 
criteria, choice and definition of primary outcomes, and intrapartum management, as 
discussed by Øian and Blix10 and Steer and Hvidman.11 Moreover, there are substantive 
differences between U.S. and European practices. We designed a large, multi-institutional, 
randomized trial to assess the effects of using fetal ECG ST-segment analysis on perinatal 
outcomes.
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STUDY DESIGN AND OVERSIGHT
The study, which consisted of a pilot phase and the randomized trial, was conducted at 16 
university-based clinical centers — each comprising 1 to 5 delivery hospitals (26 total) — in 
the Eunice Kennedy Shriver National Institute of Child Health and Human Development 
(NICHD) Maternal–Fetal Medicine Units (MFMU) Network. The protocol was approved by 
the institutional review board at each hospital and is available with the full text of this article 
at NEJM.org. Written informed consent was obtained from all participants before 
participation. A small group of investigators (protocol subcommittee) provided oversight for 
the trial. The study was supported by the NICHD and by funding from the manufacturer 
(Neoventa Medical). Neoventa did not participate in the monitoring of the study; data 
collection, management, or analysis; or manuscript preparation. The first, second, third, and 
fifth authors take responsibility for the fidelity of the report to the study protocol and for the 
accuracy and completeness of the reported data.
CERTIFICATION, TRAINING, AND PILOT PHASE
All participating care providers and research personnel were trained and certified in the 
correct use of the fetal ECG ST-segment analysis system to a level exceeding FDA 
requirements. Each hospital participated in a pilot phase that consisted of enrollment and 
care of at least 50 patients monitored with fetal ECG ST-segment analysis, with central 
review of labor-management decisions and retraining as needed before approval of the 
hospital to start the trial. Details of the certification and monitoring process are provided in 
the Supplementary Appendix, available at NEJM.org; guidelines for the management of 
labor on the basis of fetal ECG analysis are summarized in Table 1, and Figure S1 in the 
Supplementary Appendix.
Once a hospital was approved to participate in the randomized trial, the independent data 
coordinating center sent a software card containing the encrypted randomization module to 
the designated local biomedical technician to be installed on the S31 monitors at that 
hospital. No other personnel had access to the software or were able to adjust the monitors. 
A separate randomization sequence was created for each monitor.
TRIAL PROTOCOL
Women with a singleton fetus at more than 36 weeks of gestation who were attempting 
vaginal delivery and had cervical dilation of 2 to 7 cm were invited to participate. The main 
exclusion criteria were noncephalic presentation, planned cesarean delivery, a need for 
immediate delivery, absent fetal heart-rate variability (amplitude range undetectable) or a 
sinusoidal pattern, minimal fetal heart-rate variability in the 20 minutes before 
randomization, or other fetal or maternal conditions that would preclude a trial of labor or 
the placement of a scalp electrode. The full eligibility criteria are provided in the 
Supplementary Appendix.
After spontaneous or artificial membrane rupture, a Goldtrace fetal scalp electrode 
(Neoventa Medical) was placed in each woman who consented to participate in the trial. If it 
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was not possible to obtain or maintain an adequate fetal ECG signal after three attempts at 
electrode placement or if an ST-segment event occurred during the attempts to obtain an 
adequate signal, the woman was excluded from randomization. Immediately after successful 
electrode placement resulting in an adequate ST-segment analysis signal, a researcher 
activated the randomization module, which then automatically set the S31 monitor into 
“masked” or “open” mode according to the internal preassigned randomization scheme.
The masked S31 monitors functioned as conventional electronic fetal heart-rate monitors. 
The care of patients in the masked group was managed at the discretion of the attending 
physician or midwife. S31 monitors in the open mode displayed ECG ST-segment 
information intended for use when uncertain fetal heart-rate patterns were detected. 
Management of the labor and delivery for women in this group was dictated by the ST-
segment analysis guidelines (Table 1, and Fig. S1 in the Supplementary Appendix). To 
monitor adherence to the guidelines, all tracings from fetuses of patients who subsequently 
had cesarean or operative vaginal (forceps or vacuum-assisted) deliveries and from fetuses 
who had ST-segment events or primary-outcome events, as well as tracings from fetuses of a 
sample of patients who subsequently had vaginal deliveries, were centrally reviewed by the 
protocol subcommittee, whose members were unaware of the outcome of the neonate. If the 
group determined that the guidelines for fetal ECG ST-segment analysis had not been 
followed, the provider received additional training.
Paired arterial and venous umbilical-cord blood gas measurements were obtained from all 
neonates. The base deficit was calculated with the use of measurements from the 
extracellular fluid and the modified Siggaard-Andersen curve.13 To be valid, the arterial pH 
had to be lower than the venous pH, and the partial pressure of arterial carbon dioxide had to 
be greater than the partial pressure of venous carbon dioxide. All enrolled women and their 
infants were followed until hospital discharge. Trained research staff collected maternal and 
perinatal data, including the interpretation by the clinical providers of the fetal heart-rate 
pattern (NICHD category12 or fetal ECG ST-segment analysis category).
PRIMARY OUTCOME
The primary outcome was a composite of intrapartum fetal death, neonatal death, an Apgar 
score of 3 or less at 5 minutes, neonatal seizure, an umbilical-artery blood pH of 7.05 or less 
with a base deficit of 12 mmol per liter or more, intubation for ventilation at delivery, or 
neonatal encephalopathy.14 This composite outcome represents a cluster of neonatal 
outcomes that manifest early, that indicate that the fetus may have been compromised during 
labor, that are associated with a risk of long-term neurologic adverse outcomes, and that 
potentially could be avoided by more prompt delivery.15 The protocol subcommittee, whose 
members were unaware of the study-group assignments, conducted chart reviews of all 
pregnancies that were designated as having met the primary outcome criteria to confirm that 
they had met these criteria and also reviewed charts of a sample of neonates who had longer 
hospital stays or who required more-than-routine resuscitation at delivery.
Maternal secondary outcomes were cesarean delivery (with indication), forceps or vacuum-
assisted delivery, chorioamnionitis, maternal blood transfusion, duration of labor after 
randomization, shoulder dystocia, postpartum endometritis, and length of hospital stay. 
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Neonatal secondary outcomes were individual components of the primary outcome, Apgar 
score at 5 minutes, umbilical-artery blood gas results, and admission to the intermediate care 
nursery or neonatal intensive care unit.
STATISTICAL ANALYSIS
We calculated that a sample size of 11,000 patients would give the study more than 85% 
power to detect a 40% reduction in the primary outcome in the open group, assuming a rate 
of 1.75% in the masked group (derived from a previous MFMU Network randomized trial 
involving women in labor at term), at a two-sided type I error rate of 5%.16 We estimated 
that with the same power and type I error rate, our sample size would also be sufficient to 
detect a 10% reduction in the cesarean-delivery rate in the open group. Given a cesarean-
delivery rate for nonreassuring fetal status as low as 5%, there was adequate power (88%) to 
detect a 25% reduction in cesarean delivery for this specific indication.
We performed an intention-to-treat analysis, in which patients were included in the group to 
which they had been randomly assigned, regardless of the completeness of ST-segment 
monitoring or provider adherence to the protocol. Categorical variables were compared with 
the use of the chi-square test or Fisher’s exact test, as appropriate. Relative risks and 95% 
confidence intervals were calculated. Interaction tests in prespecified subgroups (category I 
vs. category II fetal heart-rate tracing at baseline, multiparous vs. nulliparous status, center, 
enrollment before vs. after the midpoint of recruitment for each site, and race or ethnic 
group) and in post hoc subgroups (induced vs. spontaneous labor and baseline cervical 
dilation of 2 to 5 cm vs. 6 to 7 cm) were conducted with the use of the Breslow–Day method 
for the following end points: primary outcome, cesarean delivery, and any operative delivery 
(cesarean and operative vaginal delivery combined). Continuous variables were compared 
with the use of the Wilcoxon rank-sum test. An independent data and safety monitoring 
committee monitored the trial for safety and trial performance. The committee did not 
review interim data on the primary outcome; therefore, no adjustment to the type I error rate 
was necessary. For all secondary outcomes, a nominal P value of less than 0.05, without 
adjustment for multiple comparisons, was considered to indicate statistical significance.
RESULTS
RECRUITMENT AND CHARACTERISTICS OF THE PARTICIPANTS
Recruitment to the pilot study started in April 2010; by April 2013, a total of 26 hospitals 
were authorized to start the randomized trial. Recruitment to the trial began in November 
2010 and ended in March 2014. A total of 43,376 women were screened for inclusion, of 
whom 18,456 did not meet eligibility criteria, 13,812 declined participation, and 11,108 
were randomly assigned to the open group (5532 women) or the masked group (5576 
women) (Fig. 1). A total of 85 women discontinued open or masked ST-segment monitoring 
before delivery; however, outcome data were obtained for all women and their neonates.
There were no significant differences in baseline characteristics between the two groups 
(Table 2). Assessment of fetal heart rate immediately before randomization showed that 
73% of fetal heart-rate tracings were NICHD category I (reassuring) and 27% were category 
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II (indeterminate)12 (Fig. S2 in the Supplementary Appendix). Of the category II tracings, 
43% had either recurrent late or recurrent variable decelerations.
OUTCOMES
Valid umbilical-cord blood gas measurements were obtained for 96.5% of all neonates. The 
primary outcome occurred in 52 neonates (0.9%) of patients in the open group and in 40 
neonates (0.7%) of patients in the masked group (relative risk, 1.31; 95% confidence 
interval, 0.87 to 1.98; P = 0.20) (Table 3). The groups did not differ significantly with 
respect to the incidences of individual components of the primary outcome, with one 
exception: the frequency of an Apgar score of 3 or less at 5 minutes was higher among 
neonates of patients in the open group than among neonates of patients in the masked group 
(0.3% vs. 0.1%; P = 0.02). However, most components of the primary outcome occurred in 
no more than 0.1% of neonates in either group.
There were no significant differences between the two groups in the overall rates of cesarean 
delivery (P = 0.30) or any operative delivery (P = 0.31). Overall, cesarean delivery because 
of fetal indications occurred in 287 women (5.2%) in the open group and 298 women (5.3%) 
in the masked group (P = 0.48). There were no significant differences between groups in any 
secondary outcomes (Table 4). Adverse events related to the ST-segment monitoring were 
rare, and the rates of individual adverse events were similar in the two groups (Table S1 in 
the Supplementary Appendix). There were no significant differences between any of the 
subgroups we assessed with respect to the effect of monitoring with ST-segment analysis on 
the primary outcome, cesarean delivery, and any operative delivery (P>0.05 for interaction 
for all comparisons) (Fig. S3, S4, and S5 in the Supplementary Appendix).
PROTOCOL ADHERENCE
The protocol subcommittee reviewed 43.9% of the tracings in the open group (2427 of 5532 
tracings): 27.3% of the tracings of fetuses later delivered by spontaneous vaginal deliveries 
(1164 of 4269 tracings), 100% of the tracings of fetuses later delivered by operative vaginal 
deliveries (329 of 329 tracings), and 100% of the tracings of fetuses later delivered by 
cesarean deliveries (934 of 934 tracings) (Table S2 in the Supplementary Appendix). 
Among the 2427 women assigned to the open group whose fetus’ tracings were reviewed, 
163 (6.7%) were determined not to have received care according to ST-segment analysis 
guidelines. In 95 cases (3.9%), expeditious delivery did not occur when recommended, and 
in 68 cases (2.8%), delivery was expedited when the guidelines indicated that continued 
observation was warranted. The primary outcome occurred in 5 of the 95 cases in which 
delivery did not occur as expeditiously as recommended and in 0 of the 68 in which delivery 
was expedited when not recommended. Even if the 5 cases were recoded as not associated 
with a primary outcome, there would be no significant difference between the two groups (P 
= 0.43). Of the 5 patients, 2 had a cesarean delivery and 3 a spontaneous vaginal delivery. 
An as-treated analysis in which patients for whom ST-segment analysis guidelines were not 
followed were included with the masked group did not reveal any significant differences 
between the groups (Table S3 in the Supplementary Appendix).
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This large, randomized trial showed that in a U.S. population of pregnant women in whom 
labor and delivery were managed according to U.S. practices, ST-segment analysis as an 
adjunct to continuous electronic fetal monitoring neither improved neonatal outcomes nor 
reduced the rates of cesarean delivery or operative vaginal delivery. Although our findings 
differ from those of two randomized trials,8,9 they are in agreement with those of other 
randomized trials.17-19 Our findings of no improvement in neonatal outcomes or reduction 
in cesarean-delivery rates are also consistent with the results of a meta-analysis of 
individual-patient data from ST-segment analysis trials,20 which showed that electronic fetal 
monitoring with adjunctive ST-segment analysis, as compared with conventional electronic 
fetal monitoring alone, did not reduce the rates of neonatal metabolic acidosis, need for 
intubation, hypoxic–ischemic encephalopathy, a composite neonatal outcome, or cesarean 
delivery.20 However, that meta-analysis showed a reduction in the frequency of fetal blood 
sampling (which is not routine in the United States) and operative vaginal delivery among 
women who underwent electronic fetal monitoring and adjunctive ST-segment analysis, as 
compared with those who underwent electronic fetal monitoring alone.20
One possible explanation for our negative findings is that clinicians did not follow the 
guidelines correctly in all cases. In the open group, 5.9% of cesarean deliveries occurred 
when ST-segment analysis guidelines indicated that labor should continue (Table S2 in the 
Supplementary Appendix). Even if these 55 cases had resulted in a vaginal delivery, there 
would have been no significant difference in the cesarean-delivery rate. A similar result is 
true for operative vaginal delivery. Moreover, if we assumed that all the cases in which 
operative delivery was indicated had actually occurred in accordance with ST-segment 
analysis guidelines and that 5 cases of the primary outcome had been avoided, the incidence 
of the primary outcome would have remained similar in the two groups.
There could have been a Hawthorne effect (the tendency for some people to perform better 
when they believe that they are being watched) resulting in improved interpretation of fetal 
heart-rate patterns, consistent with the suggestion that a systematic approach to fetal 
monitoring, rather than ST-segment analysis itself, may be what is effective.11 It has also 
been suggested that there is a learning curve with ST-segment analysis. A reanalysis of the 
meta-analysis by Schuit et al. showed that labor management with the use of ST-segment 
analysis reduced metabolic acidosis and adverse neonatal outcomes in the second half of the 
trials.21,22 We incorporated a pilot phase in our study; moreover, our preplanned analysis of 
the first 50% of randomly assigned women according to center as compared with the second 
50% showed no significant differences.
The frequency of operative vaginal delivery in our trial was lower than the 13 to 14% 
frequency in the meta-analysis by Schuit et al.20 Operative vaginal delivery is much more 
common in Europe than in the United States23 where the current rate is approximately 3%.24 
In addition, two aspects of fetal heart-rate monitoring practice in Europe differ from the 
practice in the United States; in Europe, there is a slower horizontal scaling (1 cm per 
minute) on monitors (resulting in a compressed view that potentially affects the 
interpretation of heart-rate variability), and fetal blood sampling (for confirming or ruling 
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out fetal acidosis) is more common. These differences could have influenced intrapartum 
care and may have contributed to differences between our results and those of European 
trials.
Our study had a lower-than-anticipated incidence of the primary outcome and, therefore, 
reduced power to show between-group differences. However, the lower boundary of the 
95% confidence interval for the relative risk of the primary outcome was 0.87, implying at 
best a reduction of 13% in the open group. This is far lower than the hypothesized effect and 
may be of questionable clinical significance. Even with lower rates of cesarean delivery and 
operative vaginal delivery than expected (16.5% and 5.9%, respectively), the trial still had 
80% power to detect relative differences of 11% and 15%, respectively, in these outcomes. 
To be eligible for ST-segment analysis, patients must have cervical dilatation of at least 2 
cm and have ruptured membranes. These women are likely to have a lower cesarean-
delivery rate than the overall rate in all women attempting vaginal delivery, some of whom 
are undergoing labor induction or in spontaneous labor at less than 2 cm. However, insofar 
as the clinical use of ST-segment analysis outside the trial would require the same eligibility 
criteria, we consider these results to be generalizable to clinical practice in the United States.
In conclusion, this large and closely monitored randomized, controlled trial showed no 
significant benefit of the adjunctive use of ST-segment analysis in reducing a composite of 
neonatal outcomes or in reducing cesarean or operative vaginal deliveries in a U.S. 
population undergoing conventional intrapartum continuous electronic fetal heart-rate 
monitoring.
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Figure 1. Enrollment and Outcomes
ECG denotes electrocardiographic.
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Table 2






Age — yr 27.4±5.9 27.2±5.8
Week of pregnancy at randomization 39.4±1.2 39.4±1.2
Race — no. (%)†
 Black 1326 (24.0) 1350 (24.2)
 White 3297 (59.6) 3281 (58.8)
 Other 909 (16.4) 945 (16.9)
Body-mass index before pregnancy‡ 27.4±7.2 27.4±7.0
Educational level — yr 12.8±2.6 12.8±2.7
Cervical dilation at randomization
  — cm
 Median 5 5
 Interquartile range 4–6 4–6
Type of labor — no. (%)
 Spontaneous 2259 (40.8) 2311 (41.4)
 Induced 3273 (59.2) 3265 (58.6)
Nulliparous — no. (%) 2354 (42.6) 2373 (42.6)
*




The body-mass index is the weight in kilograms divided by the square of the height in meters.
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Table 3







(95% CI) P Value
no. (%)
Primary composite outcome† 52 (0.94) 40 (0.72) 1.31 (0.87–1.98) 0.20
Intrapartum fetal death 0 0
Neonatal death 3 (0.05) 1 (0.02) 3.02 (0.31–29.1) 0.37
Apgar score ≤3 at 5 min 17 (0.31) 6 (0.11) 2.86 (1.13–7.24) 0.02
Neonatal seizure 3 (0.05) 4 (0.07) 0.76 (0.17–3.38) 1.0
Umbilical-artery blood pH ≤7.05 and
 base deficit in extracellular fluid
 ≥12 mmol/liter‡
3 (0.06) 8 (0.15) 0.37 (0.10–1.41) 0.13
Intubation for ventilation at delivery 42 (0.76) 27 (0.48) 1.57 (0.97–2.54) 0.07
Neonatal encephalopathy 4 (0.07) 5 (0.09) 0.81 (0.22–3.00) 1.0
*
CI denotes confidence interval.
†
The primary outcome was a composite of intrapartum fetal death, neonatal death, an Apgar score of 3 or less at 5 minutes, neonatal seizure, an 
umbilical-artery blood pH of 7.05 or less with a base deficit of 12 mmol per liter or more, intubation for ventilation at delivery, or neonatal 
encephalopathy.
‡
Data were available for 5362 patients in the open group and 5359 in the masked group. An umbilical-artery blood pH of 7.05 or less and a base 
deficit in blood (not extracellular fluid) of 12 mmol per liter or more occurred in 34 deliveries (0.6%) in the open group and 39 deliveries (0.7%) in 
the masked group (relative risk, 0.87; 95% CI, 0.55 to 1.38; P = 0.56).
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Table 4





(N = 5576) P Value
Maternal
Delivery method — no. (%) 0.17
 Spontaneous 4269 (77.2) 4348 (78.0)
 Forceps 128 (2.3) 103 (1.8)
 Vacuum-assisted 201 (3.6) 224 (4.0)
 Cesarean 934 (16.9) 901 (16.2)
Indication for cesarean delivery — no./total no. (%) 0.45†
 Fetal indication‡ 287/934 (30.7) 298/901 (33.1)
 Dystocia 621/934 (66.5) 583/901 (64.7)
 Other 26/934 (2.8) 20/901 (2.2)
Indication for forceps or vacuum-assisted delivery
  — no./total no. (%)
0.94†
 Fetal indication‡ 225/329 (68.4) 218/327 (66.7)
 Dystocia 95/329 (28.9) 101/327 (30.9)
 Other 9/329 (2.7) 8/327 (2.4)
Duration of labor after randomization — hr
 Median 3.8 3.9 0.32
 Interquartile range 2.1–6.4 2.2–6.7
Shoulder dystocia — no. (%) 141 (2.5) 158 (2.8) 0.35
Chorioamnionitis — no. (%) 286 (5.2) 269 (4.8) 0.40
Blood transfusion — no. (%) 80 (1.4) 74 (1.3) 0.59
Postpartum endometritis — no. (%) 71 (1.3) 88 (1.6) 0.19
Hospital stay — days
 Median 2 2 0.77
 Interquartile range 2–2 2–2
Neonatal
Apgar score at 5 min
 Median 9 9 0.54
 Interquartile range 9–9 9–9
Nursery admission — no. (%) 0.28
 Well-baby nursery 5034 (91.0) 5106 (91.6)
 Intermediate care nursery or NICU 498 (9.0) 470 (8.4)
Meconium aspiration syndrome — no. (%) 20 (0.4) 20 (0.4) 0.98
Major congenital malformation — no. (%) 38 (0.7) 23 (0.4) 0.05
*
Plus–minus values are means ±SD. NICU denotes neonatal intensive care unit.
†
The P value was calculated on the basis of the entire cohort.
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‡
Fetal indication was determined according to fetal electrocardiographic ST-segment analysis guidelines in the open group and according to 
NICHD guidelines12 for fetal heart-rate monitoring in the masked group.
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